<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">For personal use. Only reproduce with permission from The Lancet</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Prof</roleName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
							<email>dalakasm@ninds.nih.gov</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Neuromuscular Diseases Section</orgName>
								<orgName type="department" key="dep2">National Institute of Neurological Disorders and Stroke</orgName>
								<orgName type="institution">National Institutes of Health</orgName>
								<address>
									<settlement>Bethesda</settlement>
									<region>MD</region>
									<country>USA (Prof</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Max Planck Institute of Neurobiology and Institute for Clinical Neuroimmunology</orgName>
								<orgName type="institution">M C Dalakas MD)</orgName>
								<address>
									<settlement>Klinikum Grosshadern</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution">Ludwig Maximilians University</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<address>
									<addrLine>10 Center Drive MSC 1382</addrLine>
									<postCode>20892-1382</postCode>
									<settlement>Bethesda</settlement>
									<region>MD</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">For personal use. Only reproduce with permission from The Lancet</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">73DD980EC00460230C5CC55F62D2D80A</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2" ident="GROBID" when="2023-03-30T18:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Prof Marinos C Dalakas</term>
					<term>Neuromuscular Diseases Section</term>
					<term>NINDS</term>
					<term>NIH</term>
					<term>Building 10</term>
					<term>Room 4N248</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Characteristic Dermatomyositis Polymyositis Inclusion-body myositis Age at onset All ages &gt;18 years &gt;50 years Familial association No No In some cases Extramuscular manifestations Yes Yes Yes Associated disorders Connective-tissue diseases* Only with scleroderma and mixed connective-tissue disease Yes, with all Yes, in up to 20% of cases Overlap syndrome † Only with scleroderma and mixed connective-tissue disease No No Systemic autoimmune diseases Rarely Frequently Infrequently Malignant disorders Yes, in up to 15% of cases No No Viruses Unproven Yes ‡ Yes ‡ Parasites and bacteria No Yes § No Drug-induced myotoxicity|| Rarely Yes No</p><p>*A dermatomyositis-like disease develops in up to 12% of patients with systemic sclerosis, and polymyositis in 5-8% of lupus patients; polymyositis is less commonly seen in patients with Sjögren's disease or rheumatoid arthritis. †Overlap denotes that certain signs are common to both disorders; by contrast, "association" denotes that two disorders can coexist. ‡HIV and HTLV-1. §Includes parasitic (protozoa, cestodes, and nematodes), tropical, and bacterial myositis (pyomyositis). ||Drugs include penicillamine (for dermatomyositis and polymyositis), zidovudine (for polymyositis), contaminated tryptophan (for a dermatomyositis-like illness), and lipidlowering drugs rarely. Other myotoxic drugs can cause myopathy but not inflammatory myopathy. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b27">29</ref> </p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>The inflammatory myopathies are a heterogeneous group of subacute, chronic, or acute acquired diseases of skeletal muscle. They have in common the presence of moderate to severe muscle weakness and inflammation in the muscle. <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref> The disorders are clinically important because they are potentially treatable. On the basis of welldefined clinical, demographic, histological, and immunopathological criteria, the inflammatory myopathies form three major and discrete groups: polymyositis, dermatomyositis, and sporadic inclusion-body myositis. <ref type="bibr" target="#b0">1</ref> This review describes current knowledge of the clinical presentation, diagnosis, pathogenesis, and treatment of polymyositis and dermatomyositis. Inclusion-body myositis, a common and important subset as recently reviewed, <ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref> is addressed only to outline its distinguishing features in the differential diagnosis of polymyositis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Epidemiology, genetics, and general clinical features</head><p>Dermatomyositis affects both children and adults, and women more than men. Polymyositis is seen after the second decade of life. Inclusion-body myositis is more common in men over the age of 50 than in other population groups. <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref> The frequencies of polymyositis and dermatomyositis as stand-alone disorders or in association with other systemic diseases are unknown. Estimates based on old diagnostic criteria, <ref type="bibr" target="#b7">8</ref> which cannot distinguish polymyositis from inclusion-body myositis, <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b2">3</ref> range from 0•6 to 1•0 per 100 000 <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref> but may not be reliable (see later). In all age-groups, dermatomyositis is the most common and polymyositis the least common; inclusion-body myositis is the commonest myopathy above the age of 50. In children, dermatomyositis is the most frequent inflammatory myopathy but polymyositis is very rare, as recently confirmed. <ref type="bibr" target="#b10">11</ref> Genetic factors may have a role, as suggested by rare familial occurrences and association with certain HLA genes, such as DRB1*0301 alleles for polymyositis and inclusion-body myositis, <ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b12">13</ref> HLA DQA1 0501 for juvenile dermatomyositis, <ref type="bibr" target="#b13">14</ref> or tumour necrosis factor 308A polymorphism for photosensitivity in dermatomyositis. <ref type="bibr" target="#b14">15</ref> Emerging information on the genetic background of various ethnic groups may allow identification of immune-response genes that predispose certain populations to polymyositis or dermatomyositis. <ref type="bibr" target="#b15">16,</ref><ref type="bibr">17</ref> Both polymyositis and dermatomyositis present with a varying degree of muscle weakness that develops slowly, over weeks to months, but acutely in rare cases. <ref type="bibr" target="#b0">1</ref> Patients report difficulty with everyday tasks, such as rising from a chair, climbing steps, stepping onto a kerb, lifting objects, or combing their hair. Fine motor movements that depend on the strength of distal muscles, such as holding or manipulating objects, are affected late in the course of dermatomyositis and polymyositis, but fairly early in sporadic inclusion-body myositis owing to prominent involvement of distal muscles, especially wrist and finger flexors. <ref type="bibr" target="#b0">1</ref> Early involvement of the quadriceps muscle and ankle dorsiflexors, causing buckling of the knees and frequent falls, is common in sporadic inclusion-body myositis. <ref type="bibr" target="#b6">7</ref> Facial muscles remain normal but mild facial muscle weakness is common in patients with sporadic</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Polymyositis and dermatomyositis</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Marinos C Dalakas, Reinhard Hohlfeld</head><p>The inflammatory myopathies, commonly described as idiopathic, are the largest group of acquired and potentially treatable myopathies. On the basis of unique clinical, histopathological, immunological, and demographic features, they can be differentiated into three major and distinct subsets: dermatomyositis, polymyositis, and inclusion-body myositis. Use of new diagnostic criteria is essential to discriminate between them and to exclude other disorders. Dermatomyositis is a microangiopathy affecting skin and muscle; activation and deposition of complement causes lysis of endomysial capillaries and muscle ischaemia. In polymyositis and inclusion-body myositis, clonally expanded CD8positive cytotoxic T cells invade muscle fibres that express MHC class I antigens, which leads to fibre necrosis via the perforin pathway. In inclusion-body myositis, vacuolar formation with amyloid deposits coexists with the immunological features. The causative autoantigen has not yet been identified. Upregulated vascular-cell adhesion molecule, intercellular adhesion molecule, chemokines, and their receptors promote T-cell transgression, and various cytokines increase the immunopathological process. Early initiation of therapy is essential, since both polymyositis and dermatomyositis respond to immunotherapeutic agents. New immunomodulatory agents currently being tested in controlled trials may prove promising for difficult cases.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Seminar</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Search strategy and selection criteria</head><p>The review is based on our own experience and research connected with these disorders as well as a comprehensive MEDLINE search on the topics of "polymyositis", "dermatomyositis", and "inflammatory myopathies". We focused on peer-reviewed works published in English in major scientific journals over the past 10 years and on reviews written by experts on this subject. All available articles were critically reviewed. Papers presenting the strongest evidence or providing important insights into the diagnosis, pathogenesis, and management of these disorders were also referred to and cited. inclusion-body myositis. <ref type="bibr" target="#b6">7</ref> The extraocular muscles are never affected, in contrast to myasthenia in which they are affected early. <ref type="bibr" target="#b0">1</ref> The neck extensor muscles may be involved, causing difficulty in holding up the head (head drop). In advanced cases, and in rare acute cases, dysphagia with choking episodes and respiratory muscle weakness occurs. Sensation remains normal. The tendon reflexes are preserved but may be absent in severely weakened or atrophied muscles. Contrary to widespread belief, myalgia is not common, occurring in less than 30% of the patients.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Specific clinical features</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dermatomyositis</head><p>Dermatomyositis is identified by a characteristic rash accompanying or, more commonly, preceding muscle weakness. The skin manifestations include a heliotrope rash (blue-purple discolouration) on the upper eyelids in many cases associated with oedema, and an erythematous rash on the face, neck, and anterior chest (in many patients in a V sign) or back and shoulders (shawl sign), knees, elbows, and malleoli; the rash can be exacerbated after exposure to the sun and is pruritic in some cases. Characteristic is the Gottron rash (figure <ref type="figure" target="#fig_1">1</ref>), a raised violaceous rash or papules at the knuckles, prominent in metacarpophalangeal and interphalangeal joints; <ref type="bibr" target="#b16">18</ref> in contrast to systemic lupus erythematosus, the rash does not involve the phalanges. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b8">9</ref> When chronic, the rash becomes scaly with a shiny appearance. Dilated capillary loops at the base of the fingernails with irregular, thickened, and distorted cuticles are also characteristic. The lateral and palmar areas of the fingers may become rough with cracked, "dirty" horizontal lines, resembling "mechanics' hands".</p><p>The weakness varies from mild to severe, leading to quadriparesis. At times the muscle strength appears normal, hence the terms dermatomyositis sine myositis or amyopathic dermatomyositis. <ref type="bibr" target="#b17">19</ref> When a muscle biopsy is taken from such cases, however, subclinical muscle involvement with perivascular and perimysial inflammation is seen. <ref type="bibr" target="#b18">20</ref> Although there may be cases of amyopathic dermatomyositis limited to the skin, we believe that amyopathic and myopathic dermatomyositis are part of the range of dermatomyositis affecting skin and muscle to a varying degree. Rarely, when the rash is transient or poorly recognised (eg, in dark-skinned people), the term dermatomyositis sine dermatitis is appropriate. In such cases, a mistaken diagnosis of polymyositis is considered, until a muscle biopsy confirms the correct diagnosis. In children, dermatomyositis resembles the adult disease, except for more frequent extramuscular manifestations (see later). A common early abnormality in children is "misery", defined as an irritable child who feels uncomfortable, has a red flush on the face, is fatigued, does not socialise, and has a varying degree of proximal muscle weakness. <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b5">6</ref> A tiptoe gait due to flexion contracture of the ankles is common. <ref type="bibr" target="#b0">1</ref> Dermatomyositis can be associated with cancer <ref type="bibr" target="#b19">21</ref> or may overlap with systemic sclerosis and mixed connective-tissue disease. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b20">22,</ref><ref type="bibr" target="#b21">23</ref> Fasciitis and thickening of the skin, as seen in chronic dermatomyositis, can also occur in patients with eosinophilia-myalgia syndrome, <ref type="bibr" target="#b22">24</ref> eosinophilic fasciitis, or macrophagic myofasciitis. <ref type="bibr" target="#b23">25</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Polymyositis</head><p>Polymyositis is best defined as a subacute myopathy that evolves over weeks to months, affects adults but rarely children, and presents with weakness of the proximal muscles. Unlike dermatomyositis in which the rash secures early recognition, the actual onset of polymyositis cannot be easily identified. <ref type="bibr" target="#b0">1</ref> Polymyositis mimics many other myopathies and remains a diagnosis of exclusion (panel). <ref type="bibr" target="#b24">[26]</ref><ref type="bibr" target="#b25">[27]</ref><ref type="bibr" target="#b26">[28]</ref><ref type="bibr" target="#b27">[29]</ref> It should be viewed as a syndrome of diverse causes that occurs separately or in association with systemic autoimmune disorders or viral infections in patients who do not have any of the exclusion criteria listed in the panel.</p><p>As a stand-alone clinical entity, polymyositis is an uncommon but frequently misdiagnosed disorder. The commonest myopathy misdiagnosed as polymyositis is inclusion-body myositis; this disorder is suspected in retrospect in many cases of presumed polymyositis that have not responded to therapy. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b6">7</ref> Especially in men older than 50 years, a polymyositis-like disease is inclusion-body myositis until proved otherwise. Other disorders misdiagnosed as polymyositis include toxic and endocrine myopathies, dermatomyositis sine dermatitis, certain dystrophies, and some slowly progressive myopathies commonly starting in late childhood (panel).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Associated clinical findings (table 1)</head><p>Extramuscular manifestations There are many manifestations outside the muscles. Joint contractures occur mostly in dermatomyositis. Dysphagia is due to involvement of the oropharyngeal striated muscles and upper oesophagus <ref type="bibr" target="#b28">30,</ref><ref type="bibr" target="#b29">31</ref> (gastrointestinal ulcerations due to vasculitis and infection were common in children with dermatomyositis before the use of immunosuppressants 2 ). Cardiac disturbances include atrioventricular conduction defects, tachyarrhythmias, myocarditis in patients with acute disease, <ref type="bibr" target="#b30">32,</ref><ref type="bibr" target="#b31">33</ref> and heart failure commonly related to hypertension from long-term steroid use. <ref type="bibr" target="#b0">1</ref> Pulmonary symptoms are due to weakness of the thoracic muscles or interstitial lung disease, <ref type="bibr" target="#b32">[34]</ref><ref type="bibr" target="#b33">[35]</ref><ref type="bibr" target="#b34">[36]</ref> which is common in patients with autoantibodies to tRNA  synthetases or a mucin-like glycoprotein (KL-6). <ref type="bibr" target="#b33">35</ref> Subcutaneous calcifications (figure <ref type="figure" target="#fig_1">1</ref>), occur only in dermatomyositis, in some cases extruding on the skin and causing ulcerations, infections, and pain, <ref type="bibr" target="#b35">37</ref> especially at sites of compression (elbows, buttocks, back). General symptoms include fever, malaise, weight loss, arthralgia, and Raynaud's phenomenon when polymyositis or dermatomyositis is associated with another connectivetissue disease.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Malignant disorders</head><p>Although all the inflammatory myopathies can have a chance association with malignant disease, especially in older age-groups, the frequency of cancer is definitely increased in dermatomyositis. <ref type="bibr" target="#b36">38</ref> A slightly increased frequency reported in polymyositis <ref type="bibr" target="#b37">39,</ref><ref type="bibr" target="#b38">40</ref> must be confirmed with use of updated diagnostic criteria. The most common cancers are those of the ovaries, gastrointestinal tract, lung, and breast and non-Hodgkin lymphomas. Continuous vigilance is required for early recognition, especially in older people and during the first 3 years after disease onset. <ref type="bibr" target="#b21">23,</ref><ref type="bibr" target="#b39">41</ref> In patients without risk factors, expensive, radiological blind searches for occult malignant disease is not practical or fruitful. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b39">41</ref> A complete annual physical examination with pelvic, breast (mammogram, if indicated), rectal (with colonoscopy, according to age and family history) radiographs and a chest film should suffice. A report that blind search with abdominal-pelvic and thoracic CT scans increased the yield by 28% <ref type="bibr" target="#b40">42</ref> needs confirmation. In Asian patients, among whom nasopharyngeal cancer is more common, careful assessment of ears, nose, and throat is suggested.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Overlap syndrome</head><p>Polymyositis and dermatomyositis are seen in association with various autoimmune and connective tissue diseases (table <ref type="table" target="#tab_0">1</ref>). The term overlap syndrome is used loosely to emphasise this association but in reality it was meant to indicate that certain clinical signs are shared by both disorders. Accordingly, it is only dermatomyositis, and not polymyositis, that truly overlaps and only with systemic sclerosis and mixed connective-tissue disease. Certain signs seen in these two disorders, such as sclerotic thickening of the dermis, contractures, oesophageal hypomotility, microangiopathy, and calcium deposits, are also present in dermatomyositis but not polymyositis; by contrast, signs of rheumatoid arthritis, lupus, or Sjögren's syndrome are rare in dermatomyositis (table <ref type="table" target="#tab_0">1</ref>). <ref type="bibr" target="#b0">1</ref> A report that dermatomyositis can overlap with lupus 43 needs confirmation. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical characteristics of polymyositis</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Myopathic weakness</head><p>Evolves over weeks to months, spares facial and eye muscles, and presents as difficulty in climbing steps, rising from a chair, lifting objects, combing hair.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disease onset Above the age of 18 years</head><p>Features the patient DOES NOT have Rash (characteristic of dermatomyositis) Family history of neuromuscular diseases Exposure to myotoxic drugs, especially penicillamine, <ref type="bibr" target="#b24">26</ref> zidovudine, <ref type="bibr" target="#b25">27</ref> and (rarely) statins The most sensitive muscle enzyme assay is creatine kinase, which is increased up to 50 times in active disease. Aspartate and alanine aminotransferases, lactate dehydrogenase, and aldolase are also increased. Although creatine kinase concentration usually parallels disease activity, it can be normal in some patients with active dermatomyositis; in the active phases of polymyositis, the creatine kinase concentration is always increased.</p><p>Needle electromyography shows increased spontaneous activity with fibrillations, complex repetitive discharges, and positive sharp waves. The voluntary motor units consist of low-amplitude polyphasic units of short duration. <ref type="bibr" target="#b42">44,</ref><ref type="bibr" target="#b43">45</ref> Although not disease specific, these findings are useful to confirm active myopathy. Presence of spontaneous activity can help to distinguish active disease from steroid-induced myopathy, except if the two coexist. <ref type="bibr" target="#b0">1</ref> The muscle biopsy is the most crucial test for establishing the diagnosis, <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b44">46</ref> but also the most common cause of misdiagnosis due to erroneous interpretation. <ref type="bibr" target="#b3">4</ref> In dermatomyositis, the inflammation is predominantly perivascular or in the interfascicular septae and around rather than within the fascicles. <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref> The intramuscular blood vessels show endothelial hyperplasia with tubuloreticular profiles, fibrin thrombi, especially in children, and obliteration of capillaries resulting in reduction of capillary density (figure <ref type="figure" target="#fig_3">2</ref>). <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b44">[46]</ref><ref type="bibr" target="#b45">[47]</ref><ref type="bibr" target="#b46">[48]</ref><ref type="bibr" target="#b47">[49]</ref> The muscle fibres undergo phagocytosis and necrosis, commonly in groups (microinfarcts) involving a portion of a muscle fasciculus, or the periphery of the fascicle, resulting in perifascicular atrophy. This atrophy, characterised by two to ten layers of atrophic fibres at the periphery of the fascicles, is diagnostic of dermatomyositis, even in the absence of inflammation (figure <ref type="figure" target="#fig_3">2</ref>). <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b44">46</ref> The skin lesions show perivascular inflammation with CD4-positive cells in the dermis; in chronic stages there is dilatation of superficial capillaries. <ref type="bibr" target="#b1">2</ref> Skin histopathology distinguishes dermatomyositis from other papulosquamous disorders but not from cutaneous lupus. <ref type="bibr" target="#b16">18</ref> In polymyositis, multifocal lymphocytic infiltrates surround and invade healthy muscle fibres (figure <ref type="figure" target="#fig_3">2</ref>). <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b44">46</ref> The inflammation is primary, a term used to indicate that lymphocytes (CD8-positive cells) invade histologically healthy muscle fibres expressing MHC class I antigens. We refer to this lesion as the CD8/MHC-I complex (see later). <ref type="bibr" target="#b48">[50]</ref><ref type="bibr" target="#b49">[51]</ref><ref type="bibr" target="#b50">[52]</ref><ref type="bibr" target="#b51">[53]</ref> In chronic stages, connective tissue is increased and may react with alkaline phosphatase. <ref type="bibr" target="#b44">46</ref> When, in  addition to primary inflammation, there are vacuolated muscle fibres with basophilic granular deposits around the edges (rimmed vacuoles) and congophilic amyloid deposits within or next to the vacuoles, the diagnosis of inclusion-body myositis is likely. <ref type="bibr" target="#b52">54,</ref><ref type="bibr" target="#b53">55</ref> Errors in the histological diagnosis of polymyositis can be avoided by three steps. First, primary inflammation should be demonstrated. This step has become an essential criterion because it distinguishes polymyositis from toxic, necrotising, or dystrophic myopathies (facioscapulohumeral; due to deficiency of dystrophin or dysferlin) in which macrophages predominate. <ref type="bibr" target="#b44">46</ref> Second, the biopsy sample should be processed for frozen sections and with enzyme histochemistry and immunohistochemistry. Paraffin embedding misdiagnoses inclusion-body myositis for polymyositis because it dissolves the redrimmed granular material, and the vacuolated fibres become indiscernible. Also, the CD8/MHC-I complex and sarcolemmal or enzymatic proteins that exclude dystrophies, metabolic myopathies, and mitochondriopathies are best demonstrated on frozen sections. Third, a repeat muscle biopsy may be necessary. Because the inflammation is spotty, taking a sample from a different muscle should be considered if a patient meets the clinical criteria (panel) but the first sample was not diagnostic. In occasional cases, muscle MRI may be useful to identify inflammatory sites and select the area for biopsy.</p><p>Other inflammatory myopathies diagnosed on the basis of distinctive clinical and histological features include: infectious (parasitic, bacterial [pyomyositis]), granulomatous, eosinophilic (polymyositis or fasciitis), and localised forms. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b54">56</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Diagnostic criteria</head><p>The subject of diagnostic criteria remains unsettled because the various proposed criteria <ref type="bibr" target="#b2">3</ref> have not been properly validated. The criteria of Bohan and Peter 8 cannot distinguish polymyositis from inclusion-body myositis or from certain dystrophies. Because the immunopathological characteristics confer specificity for each subset, we believe that the diagnostic criteria should rely on histopathology and immunopathology as the best means of separating polymyositis from other myopathies. <ref type="bibr" target="#b0">1</ref> Accordingly, we view the diagnosis of polymyositis as definite if a patient has an acquired, subacute myopathy meeting the inclusion and exclusion criteria (panel), raised concentrations of serum creatine kinase, and primary inflammation in the muscle biopsy (table 2). When in such a patient, the biopsy sample shows widespread expression of MHC-I antigens <ref type="bibr" target="#b55">57,</ref><ref type="bibr" target="#b56">58</ref> but no T cells or vacuoles, the diagnosis is probable polymyositis. Because the same histology may also be seen in some patients who have the typical inclusion-body myositis phenotype (probable inclusion-body myositis), <ref type="bibr" target="#b57">59</ref> the diagnosis is aided by taking a second biopsy sample and relating the findings to the clinical picture.</p><p>The diagnosis of dermatomyositis is definite if the myopathy is accompanied by the characteristic rash and histopathology. If no rash is detected but the biopsy sample is typical for dermatomyositis, the diagnosis is probable dermatomyositis; conversely, if the typical dermatomyositis rash is present but muscle weakness is not apparent, the clinical diagnosis is amyopathic dermatomyositis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunopathogenesis</head><p>The autoimmune origin of polymyositis and dermatomyositis is supported by their association with other autoimmune disorders, autoantibodies, <ref type="bibr" target="#b58">60</ref> and histocompatibility genes; the evidence of T-cell-mediated myocytotoxicity or complement-mediated microangiopathy; the possible maternal microchimerism in juvenile forms; <ref type="bibr" target="#b59">61</ref> and their response to immunotherapies. However, no specific target antigens have been identified, and the agents initiating self-sensitisation remain unknown.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Autoantibodies</head><p>Autoantibodies against nuclear or cytoplasmic antigens, directed against ribonucleoproteins involved in protein synthesis (anti-synthetase) or translational transport (anti-signal-recognition particle), are found in about 20% of patients (table <ref type="table" target="#tab_5">3</ref>). <ref type="bibr" target="#b58">60</ref> These antibodies are useful clinical markers because of their frequent association with interstital lung disease. The antibody against histidyl-tRNA synthetase, anti-Jo-1, accounts for 80% of all the anti-synthetases and seems to confer specificity for identifying a disease subset that combines myositis, nonerosive arthritis, and Raynaud's phenomenon. The importance of these antibodies and their specificity in the pathogenesis of polymyositis and dermatomyositis remains unclear because they are not specific for tissue or disease subset, they occur in less than 25% of patients, and they do occur in patients with interstitial lung disease without myositis. <ref type="bibr" target="#b60">62,</ref><ref type="bibr" target="#b61">63</ref> A report that antibodies to signalrecognition particles are markers of aggressive disease with cardiomyopathy and poor response to therapies <ref type="bibr" target="#b62">64</ref> has not been confirmed. <ref type="bibr" target="#b63">65</ref> Other autoantibodies include anti-Mi-2, anti-polymyositis-Scl, found in dermatomyositis with scleroderma, and anti-KL6 associated with interstitial lung disease (table <ref type="table" target="#tab_5">3</ref>).  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunopathology of dermatomyositis</head><p>The primary antigenic target in dermatomyositis is the endothelium of the endomysial capillaries (figure <ref type="figure" target="#fig_4">3</ref>). The disease begins when putative antibodies directed against endothelial cells activate complement C3. Activated C3 leads to formation of C3b, C3bNEO, and C4b fragments and C5b-9 membranolytic attack complex (MAC), the lytic component of the complement pathway. <ref type="bibr" target="#b47">49,</ref><ref type="bibr" target="#b64">66,</ref><ref type="bibr" target="#b65">67</ref> MAC, C3b, and C4b are detected early in the patients' serum <ref type="bibr" target="#b66">68</ref> and are deposited on capillaries before inflammatory or structural changes are seen in the muscle. <ref type="bibr" target="#b47">49,</ref><ref type="bibr" target="#b64">66,</ref><ref type="bibr" target="#b65">67</ref> Sequentially, the complement deposits induce swollen endothelial cells, vacuolisation, capillary necrosis, perivascular inflammation, ischaemia, and destruction of muscle fibres. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b44">46,</ref><ref type="bibr" target="#b51">53</ref> The characteristic perifascicular atrophy (figures 2 and 3) reflects endofascicular hypoperfusion, which is prominent distally. Finally, there is striking reduction in the number of capillaries per muscle fibre with compensatory dilatation of the lumen of the remaining capillaries. <ref type="bibr" target="#b44">46,</ref><ref type="bibr" target="#b51">53</ref> Cytokines and chemokines <ref type="bibr" target="#b67">[69]</ref><ref type="bibr" target="#b68">[70]</ref><ref type="bibr" target="#b69">[71]</ref><ref type="bibr" target="#b70">[72]</ref> related to complement activation are released; they upregulate vascular-cell adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1) on the endothelial cells and facilitate the egress of activated T cells to the perimysial and endomysial spaces (figure <ref type="figure" target="#fig_4">3</ref>). T cells and macrophages through their integrins (very late activation antigen 4 and leucocyte-function-associated antigen 1) bind to the adhesion molecules and pass into the muscle through the endothelial cell wall. The predominant lymphocytes are B cells and CD4-positive T cells, consistent with a humorally mediated process. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b47">[49]</ref><ref type="bibr" target="#b48">[50]</ref><ref type="bibr" target="#b49">[51]</ref><ref type="bibr" target="#b50">[52]</ref><ref type="bibr" target="#b51">[53]</ref><ref type="bibr" target="#b71">73</ref> Gene expression profiling in muscles of genetically susceptible children showed interferon inducible genes implying virusdriven autoimmune dysregulation. <ref type="bibr" target="#b72">74</ref> However, no viruses have been amplified.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunopathology of polymyositis</head><p>In polymyositis and inclusion-body myositis, CD8positive cells invade MHC-I-antigen expressing muscle fibres. <ref type="bibr" target="#b48">[50]</ref><ref type="bibr" target="#b49">[51]</ref><ref type="bibr" target="#b50">[52]</ref><ref type="bibr" target="#b51">[53]</ref> Cytotoxic T cells T-cell lines established from muscle biopsy material are cytotoxic to autologous myotubes. <ref type="bibr" target="#b73">75</ref> In vivo, the CD8positive cells send spike-like processes into non-necrotic muscle fibres, traverse the basal lamina, and focally invade the muscle cell. <ref type="bibr" target="#b71">73</ref> The autoinvasive cells express the memory and activation markers CD45RO and ICAM-1 <ref type="bibr">76</ref> SEMINAR 976   and contain perforin and granzyme granules that are directed towards the surface of the fibres. <ref type="bibr" target="#b76">77</ref> Thus, the perforin pathway seems to be the major cytotoxic effector mechanism. By contrast, the Fas-Fas-L-dependent apoptotic process is not functionally involved, <ref type="bibr" target="#b77">78</ref> despite expression of Fas antigen on muscle fibres and Fas-L on the autoinvasive CD8-positive cells. <ref type="bibr" target="#b78">[79]</ref><ref type="bibr" target="#b79">[80]</ref><ref type="bibr" target="#b80">[81]</ref> The coexpression of the anti-apoptotic molecules BCL2, <ref type="bibr" target="#b78">79</ref> FLICE (Fasassociated death domain-like interleukin-1-convertingenzyme inhibitory protein [FLIP]), <ref type="bibr" target="#b81">82</ref> and human IAP-like protein (hILP), <ref type="bibr" target="#b82">83</ref> may confer resistance of muscle to Fasmediated apoptosis (figure <ref type="figure" target="#fig_5">4</ref>).</p><p>In polymyositis and inclusion-body myositis but not dermatomyositis, certain CD8-positive cells of specific T-cell-receptor (TCR) families are clonally expanded both in the circulation and in muscle. <ref type="bibr" target="#b83">[84]</ref><ref type="bibr" target="#b84">[85]</ref><ref type="bibr" target="#b85">[86]</ref><ref type="bibr" target="#b86">[87]</ref><ref type="bibr" target="#b87">[88]</ref><ref type="bibr" target="#b88">[89]</ref> In individual patients, the CDR3 region, the antigen-binding region of the TCR of the autoinvasive CD8-positive cells, has conserved aminoacid sequences, which suggest that T-cell expansion is driven by a common antigen, possibly an autoantigen. <ref type="bibr" target="#b84">[85]</ref><ref type="bibr" target="#b85">[86]</ref><ref type="bibr" target="#b86">[87]</ref><ref type="bibr" target="#b87">[88]</ref> Remarkably, only the autoinvasive (autoaggressive) T cells are clonally expanded; the noninvasive bystander T cells are clonally diverse. <ref type="bibr" target="#b84">85</ref> In one case, a single clone of ␥/␦ T cells of a single clone were the primary cytotoxic effectors. <ref type="bibr" target="#b89">[90]</ref><ref type="bibr" target="#b90">[91]</ref><ref type="bibr" target="#b91">[92]</ref> When the ␥/␦ TCR of these cells was transfected into a TCR-deficient mouse hybridoma cell line, <ref type="bibr" target="#b91">92</ref> the transfectants could be stimulated with an unknown autoantigen on human myoblasts. <ref type="bibr" target="#b91">92</ref> This is the first indication that in ␥/␦-T-cell mediated polymyositis the autoaggressive T cells recognise muscle antigens.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MHC expression</head><p>Muscle fibres do not normally express MHC class I or II antigens. In polymyositis and inclusion-body myositis, however, widespread overexpression of MHC class I, and occasionally MHC II, is seen even in areas remote from the inflammation. <ref type="bibr" target="#b55">57,</ref><ref type="bibr" target="#b56">58,</ref><ref type="bibr" target="#b92">93</ref> In human myotubes, MHC molecules are upregulated by interferon ␥. <ref type="bibr" target="#b93">[94]</ref><ref type="bibr" target="#b94">[95]</ref><ref type="bibr" target="#b95">[96]</ref> Although in transgenic mice MHC-I expression was proposed to act as an inciting event triggering polymyositis with myositisspecific antibodies, <ref type="bibr" target="#b96">97</ref> the observed histopathology was not typical of myositis. Furthermore, in human polymyositis upregulation of MHC-I alone does not trigger T-cell activation or endomysial infiltration. <ref type="bibr" target="#b97">98</ref> Another MHC molecule, the non-polymorphic non-classic HLA G, is upregulated in vitro by interferon ␥ and is expressed on muscle fibres of patients with polymyositis (and inclusionbody myositis). <ref type="bibr" target="#b98">99</ref> Because HLA G protects human muscle cells from immune-cell-mediated lysis in vitro, it could also partially protect muscle fibres in vivo. <ref type="bibr">100</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Costimulatory molecules</head><p>If the autoinvasive CD8-positive cells are driven by specific antigens, as the clonally expanded TCR gene rearrangements indicate, <ref type="bibr" target="#b83">[84]</ref><ref type="bibr" target="#b84">[85]</ref><ref type="bibr" target="#b85">[86]</ref><ref type="bibr" target="#b86">[87]</ref><ref type="bibr" target="#b87">[88]</ref><ref type="bibr">101</ref> the MHC-I molecule on the muscle fibres should be able to present antigenic peptides to the TCR. For primary T-cell antigenic stimulation a second signal is required and provided by the B7 family of costimulatory molecules. 102,103 Muscle fibres do not express the classic costimulatory molecules B7-1 (CD80) or B7-2 (CD86); 104 instead, they express a functional B7-related molecule defined by the monoclonal antibody BB-1. 104 Indeed, the MHC-I/BB1-positive muscle fibres make direct cell-to-cell contact with their CD28 or CTLA-4 ligands on the autoinvasive CD8positive cells (figure <ref type="figure" target="#fig_5">4</ref>). <ref type="bibr">104,</ref><ref type="bibr">105</ref> The B7-related costimulatory molecule LICOS (ligand of inducible costimulator) and the costimulatory molecule CD40 are also upregulated on muscle fibres. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cytokines, cytokine signalling, chemokines, and metalloproteinases</head><p>In the muscles of patients with polymyositis or dermatomyositis, there is overexpression of the signal transduction and activation of transducers type I, 108 indicating cytokine upregulation. Various cytokines and their mRNA, including interleukins 1, 2, 6, and 10, tumour necrosis factor ␣, interferon ␥, and transforming growth factor ␤, are amplified in polymyositis and dermatomyositis. <ref type="bibr" target="#b67">69,</ref><ref type="bibr" target="#b69">71,</ref><ref type="bibr" target="#b70">72,</ref><ref type="bibr">[109]</ref><ref type="bibr">[110]</ref><ref type="bibr">[111]</ref> Some of them, such as interferon ␥ and interleukin 1b, may have a myocytotoxic effect <ref type="bibr">[112]</ref><ref type="bibr">[113]</ref><ref type="bibr">[114]</ref> whereas others, such as transforming growth factor ␤, may promote chronic inflammation and fibrosis. <ref type="bibr">115</ref> Muscle-fibre necrosis occurs via the perforin granules released by the autoaggressive T cells. Death of the muscle fibre is mediated by a form of necrosis rather than apoptosis, presumably because of the counterbalancing effect or protection by the antiapoptotic molecules BCL2, hILP, and FLIP which are upregulated in polymyositis and inclusion-body myositis. Fas is also expressed, but it does not mediate apoptosis in the muscle. The upregulated NCAM on degenerating muscle fibres may enhance regeneration. After successful immunotherapy, 116 there is downregulation of cytokines with reduction of inflammation and fibrosis. <ref type="bibr">116,</ref><ref type="bibr">117</ref> Chemokines, a class of small cytokines, 118 including interleukin 8 (CXCL8), RANTES (CCL9), MCP-1 (CCL2), Mig CXCL9), and IP-10 (CXCL10) are also overexpressed in the endomysial inflammatory cells, the extracellular matrix, and the muscle fibres; <ref type="bibr" target="#b70">72,</ref><ref type="bibr">[119]</ref><ref type="bibr">[120]</ref><ref type="bibr">[121]</ref> they may facilitate trafficking of activated T cells to the muscle or promote tissue fibrosis. The matrix metalloproteinases MMP-2 and MMP-9, which promote the migration of lymphocytes through extracellular matrix, are also overexpressed on the muscle fibres and the autoinvasive CD8-positive cells. <ref type="bibr">122,</ref><ref type="bibr">123</ref> Viral infections Although several viruses (coxsackieviruses, influenza, parvoviruses, paramyxoviruses, cytomegalovirus, Epstein-Barr virus) and bacteria (Borrelia burgdorferi, streptococci) have been indirectly associated with chronic and acute myositis, <ref type="bibr" target="#b13">14,</ref><ref type="bibr">124</ref> sensitive PCR studies have not amplified viral genome from muscle of these patients. <ref type="bibr">125,</ref><ref type="bibr">126</ref> A proposed molecular mimicry based on structural homology between coxsackieviruses and Jo-1 synthethase has not been proved. <ref type="bibr">124</ref> The best evidence of a viral connection is with retroviruses. At least six different retroviruses have been associated with polymyositis and inclusion-body myositis. <ref type="bibr">124,</ref><ref type="bibr">[127]</ref><ref type="bibr">[128]</ref><ref type="bibr">[129]</ref><ref type="bibr">[130]</ref><ref type="bibr">[131]</ref><ref type="bibr">[132]</ref> Monkeys infected with simian immunodeficiency virus, 127 and human beings infected with HIV and HTLV-1, 128,129 develop polymyositis either as an isolated clinical entity or concurrently with other manifestations of AIDS or HTLV-1 infection. <ref type="bibr">[128]</ref><ref type="bibr">[129]</ref><ref type="bibr">[130]</ref><ref type="bibr">[131]</ref><ref type="bibr">[132]</ref><ref type="bibr">[133]</ref> HIV seroconversion may coincide with myoglobulinuria and acute myalgia, suggesting that myotropism for HIV can be symptomatic early in the infection. The retroviruses are found only in occasional endomysial macrophages <ref type="bibr">[129]</ref><ref type="bibr">[130]</ref><ref type="bibr">[131]</ref><ref type="bibr">[132]</ref><ref type="bibr">[133]</ref> and do not replicate within the muscle fibres or cause persistent infection. <ref type="bibr">[131]</ref><ref type="bibr">[132]</ref><ref type="bibr">[133]</ref> In HIV-1 and HTLV-1 polymyositis, CD8-positive, nonviral-specific, cytotoxic T cells invade MHC-I-antigenexpressing non-necrotic muscle fibres in a pattern identical to retrovirus-negative polymyositis. Virusinduced cytokines, secreted also in situ by the virusinfected macrophages, could trigger T-cell activation and MHC upregulation. The relation between systemic retroviral infection and local autoimmune processes in muscle is not precisely understood. In principle, there are two possibilities: either the autoimmune attack is triggered by mimicry between retroviral and muscle antigens, or the autoimmune process is non-specifically induced via bystander stimulation. <ref type="bibr">134</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment</head><p>The goals of therapy are to improve the ability to carry out activities of daily living by increasing muscle strength and to ameliorate extramuscular manifestations (rash, dysphagia, dyspnoea, arthralgia, fever). There have been very few controlled clinical trials, most on dermatomyositis and inclusion-body myositis. <ref type="bibr">135</ref> Overall, dermatomyositis responds better than polymyositis, and inclusion-body myositis is difficult to treat. Although when the strength improves, the serum creatine kinase concentration falls concurrently, the reverse is not always true because treatments (eg, plasmapheresis) can lower the serum creatine kinase concentration without improving strength. <ref type="bibr" target="#b0">1</ref> This effect has been misinterpreted as "chemical improvement", and has formed the basis for the common habit of "chasing" or "treating" the creatine kinase concentration instead of the muscle weakness. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b5">6,</ref><ref type="bibr">135</ref> The following agents are used in the treatment of polymyositis and dermatomyositis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Corticosteroids</head><p>Prednisone is the first-line drug, but its application remains empirical. We start with 80-100 mg per day for 3-4 weeks, and taper the dose over 10 weeks to alternateday administration. Although most patients respond to some degree and for some time, others become steroid resistant and the addition of an immunosuppressive drug becomes necessary. The decision to initiate such therapy is based on: the need for a steroid-sparing effect, when despite steroid responsiveness the patients develop complications; the inability to lower the high steroid dose without precipitating a relapse; ineffectiveness of a 2-3-month course of high-dose prednisone; and rapidly progressive weakness and respiratory failure. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b5">6,</ref><ref type="bibr">135</ref> Immunosuppressive drugs Selection of an immunosuppressive drug remains empirical and depends on personal experience and the relative efficacy/safety ratio. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b5">6,</ref><ref type="bibr">135,</ref><ref type="bibr">136</ref> Azathioprine (orally, 2•5-3•0 mg/kg) takes 4-6 months to work. A controlled trial in 1980 showed benefit of azathioprine. 137 Methotrexate (orally, up to 25 mg weekly) acts more quickly than azathioprine. A rare side-effect is pneumonitis, which may be difficult to distinguish from the interstitial lung disease associated with Jo-1 antibodies. Cyclosporin (orally, 100-150 mg twice daily) 138 may also benefit childhood dermatomyositis. <ref type="bibr">139</ref> Mycophenolate mofetil (2 g per day) is emerging as a promising and well tolerated drug. 140 Cyclophosphamide (0•5-1•0 g/m 2 ) intravenously has shown mixed results; 141,142 it may help patients with interstitial lung disease, but the evidence remains circumstantial. <ref type="bibr">143</ref> Other treatments Plasmapheresis was not found to be helpful in a doubleblind, placebo-controlled study. <ref type="bibr">144</ref> Total lymphoid irradiation has helped in a few patients but its long-term side-effects curtail its use. <ref type="bibr">145</ref> Intravenous immunoglobulin (2 g/kg) in uncontrolled series was promising. <ref type="bibr">146</ref> In the first double-blind study conducted for dermatomyositis, intravenous immunoglobulin was effective not only in improving muscle strength but also in resolving the underlying immunopathology, as shown by repeated muscle biopsies. <ref type="bibr">116</ref> The improvement can be impressive; it begins after the first infusion but is short lived in most cases, and repeated infusions every 6-8 weeks are needed. <ref type="bibr">116,</ref><ref type="bibr">[147]</ref><ref type="bibr">[148]</ref><ref type="bibr">[149]</ref> In polymyositis, no controlled studies have been completed, but intravenous immunoglobulin seems to be effective in about 70% of patients.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Our approach</head><p>The following sequential, step-by-step, empirical escalating approach has been successful in our patients.</p><p>Step 1 is prednisone. Step 2 is azathioprine or methotrexate (methotrexate acts faster but no comparative trials are available; 150 the choice depends on personal experience). In aggressive cases, steps 1 and 2 may be combined from the outset. Step 3 is intravenous immunoglobulin (this may be used as step 2). Step 4 is cyclosporin, mycophenolate mofetil, chlorambucil, or cyclophosphamide, used individually or in various combinations with steps 1-3, 150 as dictated by disease severity, coexisting disorders, or the patient's age. Superiority of a specific combination remains unproven. <ref type="bibr">150</ref> Future immunotherapies Although antigen-specific therapies are not in the offing, some rational therapeutic approaches are currently being investigated with agents that: block signal transduction in T lymphocytes (such as FK506, rapamycin, CAMPATH, or monoclonal antibodies against costimulatory molecules CD28/CTLA-4); 151-153 are directed against cytokines, such as monoclonal antibodies against tumour necrosis factor ␣, soluble receptors to tumour necrosis factor ␣, and ␤ interferons; and interfering with integrins and their receptors. <ref type="bibr">[151]</ref><ref type="bibr">[152]</ref><ref type="bibr">[153]</ref> Prognosis Although the disease outcome has substantially improved, at least a third of patients are left with mild to severe disability. <ref type="bibr">[154]</ref><ref type="bibr">[155]</ref><ref type="bibr">[156]</ref> Older age and association with cancer are factors associated with poor prognosis. Pulmonary fibrosis, frequent aspiration pneumonias due to oesophageal dysfunction, and calcinosis in dermatomyositis are associated with increased morbidity. <ref type="bibr">[154]</ref><ref type="bibr">[155]</ref><ref type="bibr">[156]</ref> In a small cohort, the 5-year survival was 95% and the 10-year survival 84%. <ref type="bibr">156</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p>On the basis of our own experience and that of others in major neuromuscular centres, the diagnosis and treatment of dermatomyositis and polymyositis could be improved by modification of many common practices. First, all disorders that mimic polymyositis should be excluded, taking into account that the criteria of Bohan and Peter cannot separate polymyositis from inclusionbody myositis or other toxic, necrotising, and dystrophic myopathies. Second, polymyositis as a stand-alone entity is rare. Although no accurate epidemiological data are available, polymyositis is rare in neuromuscular clinics; inclusion-body myositis is more common. Third, endomysial inflammation also occurs in non-immune myopathies (dystrophies, toxic, metabolic). Fourth, muscle tested with needle electromyography should not be sampled by biopsy until a month later. Fifth, in patients presenting with fatigue and increased activities of serum aminotransferases or lactate dehydrogenase, the creatine kinase concentration should be also checked to exclude myogenic origin of increased "liver enzymes" and avoid misdirection towards liver disease and liver biopsy. Sixth, patients with active polymyositis have muscle weakness; patients presenting with myalgias but normal strength do not have polymyositis. Seventh, if primary inflammation (CD8-positive/MHC-I complex) is not demonstrable, the diagnosis of polymyositis is doubtful. Eighth, the goal of therapy is to improve strength; creatine kinase is a good indicator of disease activity but not the target of therapy. Ninth, when therapies for presumed polymyositis have lowered the creatine kinase concentration but not improved strength, the patient should be reassessed, the muscle biopsy sample re-examined, and a second biopsy considered to exclude inclusion-body myositis or dystrophy. Finally, when the patient's strength has improved but is not fully restored, maintenance therapy with immunosuppressive drugs or alternate-day prednisone should be continued.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>SEMINAR 972 THE</head><label>972</label><figDesc>LANCET • Vol 362 • September 20, 2003 • www.thelancet.com</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1 :</head><label>1</label><figDesc>Figure 1: Rash and calcifications in dermatomyositis A: Gottron's rash. B: Skin effects of calcification. C: Radiographic evidence of calcification.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc>SEMINAR 974 THE LANCET • Vol 362 • September 20, 2003 • www.thelancet.com</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 2 :</head><label>2</label><figDesc>Figure 2: Histological findings in polymyositis and dermatomyositisA, B: Depletion of capillaries in dermatomyositis (A) with dilatation of the lumen of the remaining capillaries, compared with a normal muscle (B). C: Perifascular atrophy in dermatomyositis. D: Endomysial inflammation in polymyositis and inclusion-body myositis with lymphocytic cells invading healthy fibres. E: The MHC-I/CD8 complex in polymyositis and inclusion-body myositis. MHC-I (green) is upregulated on all the muscle fibres, and CD8-positive T cells (orange) that also express MHC-I, invade the fibres.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 3 :</head><label>3</label><figDesc>Figure 3: Proposed sequence of immunopathological changes in dermatomyositis VLA-4=very late activation antigen; LFA-1=leucocyte-function-associated antigen; NO=nitric oxide; TNF␣=tumour necrosis factor ␣; TGF␤=transforming growth factor ␤. Modified from reference 53.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 4 :</head><label>4</label><figDesc>Figure 4: Molecules, receptors, and ligands involved in transgression of T cells through endothelial cell wall and recognition of antigens on muscle fibres in polymyositis Modified from references 55 and 89.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 :</head><label>1</label><figDesc>Conditions and factors associated with inflammatory myopathies</figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head></head><label></label><figDesc>Myopathic muscle weakness, affecting proximal muscles more than distal ones and sparing eye and facial muscles, is characterised by a subacute onset (weeks to months) and rapid progression in patients who have no family history of neuromuscular disease, no exposure to myotoxic drugs or toxins, and no signs of biochemical muscle disease. The myopathic weakness has a pattern distinct from that seen in inclusion-body myositis (table1). †Although strength is apparently normal, many patients have new onset of easy fatigue, myalgia, and reduced endurance. Careful muscle testing may reveal mild muscle weakness. ‡If such a patient has the clinical phenotype of sporadic inclusion-body myositis, the diagnosis will be probable inclusion-body myositis; a repeat biopsy is indicated.</figDesc><table><row><cell>Criterion</cell><cell>Polymyositis</cell><cell></cell><cell cols="2">Myopathic dermatomyositis</cell><cell>Amyopathic</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>dermatomyositis</cell></row><row><cell></cell><cell>Definite</cell><cell>Probable</cell><cell>Definite</cell><cell>Probable</cell><cell>Definite</cell></row><row><cell cols="2">Myopathic muscle weakness Yes*</cell><cell>Yes*</cell><cell>Yes*</cell><cell>Yes*</cell><cell>No †</cell></row><row><cell>Electromyographic findings</cell><cell>Myopathic</cell><cell>Myopathic</cell><cell>Myopathic</cell><cell>Myopathic</cell><cell>Myopathic or</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>non-specific</cell></row><row><cell>Muscle enzymes</cell><cell>High (up to 50</cell><cell>High (up to 50 times</cell><cell>High (up to 50 times</cell><cell>High</cell><cell>High (up to 10 times</cell></row><row><cell></cell><cell>times normal)</cell><cell>normal)</cell><cell>normal) or normal</cell><cell></cell><cell>normal) or normal</cell></row><row><cell>Muscle-biopsy findings</cell><cell cols="2">Primary inflammation, Ubiquitous MHC-I</cell><cell cols="3">Perifascicular, perimysial Perifascicular, perimysial Non-specific or</cell></row><row><cell></cell><cell cols="2">with the CD8/MHC-1 expression, but no</cell><cell cols="3">or perivascular infiltrates; or perivascular infiltrates; diagnostic for</cell></row><row><cell></cell><cell>complex and no</cell><cell cols="2">CD8-positive infiltrates perifascicular atrophy</cell><cell>perifascicular atrophy</cell><cell>dermatomyositis</cell></row><row><cell></cell><cell>vacuoles</cell><cell>or vacuoles ‡</cell><cell></cell><cell></cell><cell>(subclinical myopathy)</cell></row><row><cell>Rash or calcinosis</cell><cell>Absent</cell><cell>Absent</cell><cell>Present</cell><cell>Not detected</cell><cell>Present</cell></row></table><note>SEMINAR THE LANCET • Vol 362 • September 20, 2003 • www.thelancet.com 975 *</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2 :</head><label>2</label><figDesc>Diagnostic criteria for inflammatory myopathies</figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head></head><label></label><figDesc>SRP=signal recognition particle. *The antibodies are found mostly in polymyositis and dermatomyositis, and occasionally in inclusion-body myositis, when the myositis is associated with another connective-tissue disorder. †Some Jo-1-positive patients with polymyositis or dermatomyositis have the triad of non-erosive arthritis, interstitial lung disease, and Raynaud's phenomenon; 50% of them have interstitial lung disease. ‡7% of these patients also have antibodies against the cognate tRNA his .</figDesc><table><row><cell>Autoantibodies associated with myositis*</cell><cell>Antigen</cell></row><row><cell cols="2">Anti-aminoacyl-tRNA synthetases (in 20% of patients)</cell></row><row><cell>Anti-Jo-1 †</cell><cell>tRNA his synthetase ‡</cell></row><row><cell>Anti-PL-7</cell><cell>tRNA thr synthetase</cell></row><row><cell>Anti-PL-12</cell><cell>tRNA ala synthetase</cell></row><row><cell>Anti-EJ</cell><cell>tRNA gly synthetase</cell></row><row><cell>Anti-OJ</cell><cell>tRNA ile synthetase</cell></row><row><cell>Anti-KS</cell><cell>tRNA asp synthetase</cell></row><row><cell>Anti-signal recognition particle</cell><cell></cell></row><row><cell>&lt;3% of patients</cell><cell>SRP-complex</cell></row><row><cell>Other</cell><cell></cell></row><row><cell>Anti-Mi-2 (10-15% of dermatomyositis and</cell><cell>Nuclear helicase</cell></row><row><cell>polymyositis)</cell><cell></cell></row><row><cell>Anti-polymyositis-Scl (15% of dermatomyositis</cell><cell>Nuclear complex</cell></row><row><cell>with scleroderma)</cell><cell></cell></row><row><cell>Anti-KL6 (in patients with interstitial lung</cell><cell>Mucin-like glycoprotein</cell></row><row><cell>disease)</cell><cell>(on alveoli or bronchial</cell></row><row><cell></cell><cell>epithelial cells)</cell></row></table><note>THE LANCET • Vol 362 • September 20, 2003 • www.thelancet.com</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 3 :</head><label>3</label><figDesc>Various autoantibodies associated with polymyositis, dermatomyositis, and some cases of inclusion-body myositis</figDesc><table /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0">THE LANCET • Vol 362 • September 20, 2003 • www.thelancet.com</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p>We thank the following for funding our studies for many years: Intramural Research Program of the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA (MCD) and Max Planck Institute of Neurobiology and Institute for Clinical Neuroimmunology, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany (RH).</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest statement</head><p>None declared.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Role of the funding source</head><p>The funding sources had no role in the preparation of this paper.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Polymyositis, dermatomyositis and inclusion-body myositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">325</biblScope>
			<biblScope unit="page" from="1487" to="1498" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">The polymyositis and dermatomyositis syndromes</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">Q</forename><surname>Banker</surname></persName>
		</author>
		<editor>Engel AG, Franzini-Armstrong C</editor>
		<imprint>
			<date type="published" when="1994">1994</date>
			<publisher>McGraw-Hill</publisher>
			<biblScope unit="page" from="1335" to="1383" />
			<pubPlace>New York</pubPlace>
		</imprint>
	</monogr>
	<note>2nd edn</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Idiopathic inflammatory myopathies: epidemiology, classification and diagnostic criteria</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Phillips</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheum Dis Clin N Am</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="723" to="741" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">The inflammatory myopathies</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Karpati</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Disorders of voluntary muscle</title>
				<editor>
			<persName><forename type="first">G</forename><surname>Karpati</surname></persName>
		</editor>
		<editor>
			<persName><surname>Hilton-Jones</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Griggs</surname></persName>
		</editor>
		<meeting><address><addrLine>Cambridge</addrLine></address></meeting>
		<imprint>
			<publisher>Cambridge University Press</publisher>
			<date type="published" when="2001">2001</date>
			<biblScope unit="page" from="636" to="659" />
		</imprint>
	</monogr>
	<note>7th edn</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">D</forename><surname>Hilton-Jones</surname></persName>
		</author>
		<author>
			<persName><surname>Inflammatory Myopathies</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Neurol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="591" to="596" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">Polymyositis, dermatomyositis and inclusion body myositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Braunwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Fauci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Kasper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Hauser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Longo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Jameson</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2001">2001</date>
			<publisher>McGraw-Hill</publisher>
			<biblScope unit="page" from="2524" to="2529" />
			<pubPlace>New York</pubPlace>
		</imprint>
	</monogr>
	<note>Harrison&apos;s principles of internal medicine. 15th edn</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Inclusion body myositis: new concepts</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Sekul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Neurol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="256" to="263" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bohan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Peter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">292</biblScope>
			<biblScope unit="page" from="403" to="407" />
			<date type="published" when="1975">1975</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis and related disorders</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Leff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Love</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Cronin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="143" to="157" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">The epidemiology of polymyositis</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Medsger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">N</forename><surname>Dawson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Masi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="715" to="723" />
			<date type="published" when="1979">1979</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Ramanan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Feldman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheum Dis Clin N Am</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="833" to="857" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Update on the genetics of the idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Shamin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Rider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="482" to="491" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Koffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sivakumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Simonis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Stroncek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuroimmunol</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="139" to="142" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Genetic and environmental risk factors for idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Reed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Ytterberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheum Dis Clin N Am</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="891" to="916" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Associations of tumor necrosis factor ␣ and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">P</forename><surname>Werth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Callen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Sullivan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="617" to="620" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Shamin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Rider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Pandey</surname></persName>
		</author>
		<ptr target="www.thelancet.com" />
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="428" to="433" />
			<date type="published" when="2001">2002. September 20. 2003. 2001</date>
		</imprint>
	</monogr>
	<note>SEMINAR THE LANCET</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Callen</surname></persName>
		</author>
		<author>
			<persName><surname>Dermatomyositis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">355</biblScope>
			<biblScope unit="page" from="53" to="57" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Sontheimer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatol Clin</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="387" to="408" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Is there dermatomyositis (DM) without myositis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Otero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Illa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page">388</biblScope>
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Relation between dermatomyositis and polymyositis and cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Callen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">357</biblScope>
			<biblScope unit="page" from="85" to="86" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Scleroderma-polymyositis overlap syndrome: clinical and serologic aspects</title>
		<author>
			<persName><forename type="first">T</forename><surname>Mimori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Dermatol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="419" to="425" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Association of inflammatory myopathies with other connective tissue disorder and malignancies</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Carry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Ringel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Polymyositis and dermatomyositis</title>
				<editor>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</editor>
		<meeting><address><addrLine>Boston: Butterworth</addrLine></address></meeting>
		<imprint>
			<date type="published" when="1988">1988</date>
			<biblScope unit="page" from="37" to="69" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Hertzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Blevins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Greenfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Gleich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">322</biblScope>
			<biblScope unit="page" from="869" to="873" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Macrophagic myofasciitis: an emerging entity</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Gherardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Coquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Chérin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">352</biblScope>
			<biblScope unit="page" from="347" to="352" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Fatal polymyositis in Dpenicillamine-treated rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Doyle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Mccurley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Sergent</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="327" to="330" />
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Mitochondrial myopathy caused by long-term zidovudine therapy</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Illa</forename><forename type="middle">I</forename><surname>Pezeshkpour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Laukaitis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Griffin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">332</biblScope>
			<biblScope unit="page" from="1098" to="1105" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Adverse effects of drugs on muscle</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drugs</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="304" to="321" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Diseases of muscle and the neuromuscular junction</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci Am</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1" to="14" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Cricopharyngeal muscle dysfunction in the differential diagnosis of dysphagia in polymyositis</title>
		<author>
			<persName><forename type="first">F</forename><surname>Dietz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Logeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Sahgal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Schmid</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="491" to="495" />
			<date type="published" when="1980">1980</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Esophageal abnormalities and dysphagia in polymyositis and dermatomyositis: clinical, radiographic and pathologic features</title>
		<author>
			<persName><forename type="first">P</forename><surname>Demerieux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Verity</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Clements</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Paulus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="961" to="968" />
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">The heart and cardiac conduction system in polymyositis-dermatomyositis: a clinicopathologic study of 16 autopsied patients</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Haupt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Hutchins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="998" to="1006" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Severe cardiac involvement in children with systemic sclerosis and myositis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Quartier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bonnet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Fournet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1767" to="1773" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Pulmonary disease in polymyositis/dermatomyositis: a clinicopathological analysis of 65 autopsy cases</title>
		<author>
			<persName><forename type="first">S</forename><surname>Lakhanpal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Lie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Conn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="23" to="29" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Interstitial lung disease in polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hirakata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nagai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="501" to="508" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Polymyositisdermatomyositis associated interstitial lung disease</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Douglas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>Tazelaar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Hartman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="page" from="1182" to="1185" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Calcifications in dermatomyositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">333</biblScope>
			<biblScope unit="page">978</biblScope>
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Risk of cancer in patients with dermatomyositis or polymyositis: a population-based study</title>
		<author>
			<persName><forename type="first">B</forename><surname>Sigurgeirsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lindelöf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Edhag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Allander</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">326</biblScope>
			<biblScope unit="page" from="363" to="367" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Incidence of malignant disease in biopsy-proven inflammatory myopathy</title>
		<author>
			<persName><forename type="first">R</forename><surname>Buchbinder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Forbes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Dennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Giles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="1087" to="1095" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Hill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sigurgeirsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">357</biblScope>
			<biblScope unit="page" from="96" to="100" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">When and how should the patient with dermatomyositis or amyopathic dermatomyositis be assessed for possible cancer?</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Callen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Dermatol</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="page" from="969" to="971" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Routine vs extensive malignancy search for adult dermatomyositis and polymyositis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sparsa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Liozon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Herrmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Dermatol</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="page" from="885" to="890" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">SLE/myositis overlap: are the manifestations of SLE different in overlap disease</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Dayal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Isenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lupus</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="293" to="298" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Quantitative EMG in inflammatory myopathy</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Barkhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Nandedkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Sanders</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="247" to="253" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Long-duration polyphasic motor unit potentials in myopathies: a quantitative study with pathological correlation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Uncini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Lange</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Hayes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="263" to="267" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Muscle biopsy findings in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheum Dis Clin N Am</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="779" to="798" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Dermatomyositis of childhood: ultrastructural alterations of muscle and intramuscular blood vessels</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">Q</forename><surname>Banker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="46" to="75" />
			<date type="published" when="1975">1975</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">The childhood type of dermatomyositis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Carpenter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Karpati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rothman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Walters</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="952" to="962" />
			<date type="published" when="1976">1976</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Microvascular changes in early and advanced dermatomyositis: a quantitative study</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Emslie-Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="343" to="356" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Monoclonal antibody analysis of mononuclear cells in myopathies: V, identification and quantitation of T8+ cytotoxic and T8 suppressor cells</title>
		<author>
			<persName><forename type="first">K</forename><surname>Arahata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="493" to="499" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Monoclonal antibody analysis of mononuclear cells in myopathies: II, phenotypes of autoinvasive cells in polymyositis and inclusion body myositis</title>
		<author>
			<persName><forename type="first">K</forename><surname>Arahata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="209" to="215" />
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">The immunobiology of muscle</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunol Today</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="269" to="274" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Immunopathogenesis of inflammatory myopathies</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="S74" to="86" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Inclusion body myositis and myopathies</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Griggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Mauro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="705" to="713" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Understanding the immunopathogenesis of inclusion body myositis: present and future prospects</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rev Neurol</title>
		<imprint>
			<biblScope unit="volume">158</biblScope>
			<biblScope unit="page" from="948" to="958" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Clinical and pathologic features of focal myositis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Urbanits</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Blaivas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Grisold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Russell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1569" to="1575" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Expression of immunoreactive major histocompatibility complex products in human skeletal muscles</title>
		<author>
			<persName><forename type="first">G</forename><surname>Karpati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Pouliot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Carpenter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="64" to="72" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes and T-cell-mediated cytotoxicity in myopathies</title>
		<author>
			<persName><forename type="first">Emslie-Smith Am</forename><surname>Arahata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Pathol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="224" to="231" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Inclusion body myositis: clinical and pathological boundaries</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Amato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Gronseth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Jackson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="581" to="586" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">N</forename><surname>Targoff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheum Dis Clin N Am</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="859" to="890" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Chimerism in children with juvenile dermatomyositis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Reed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Picornell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Harwood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kredich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">356</biblScope>
			<biblScope unit="page" from="2156" to="2157" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Friedman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">N</forename><surname>Targoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Arnett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="459" to="467" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Myositis-specific autoantibodies: overview and recent developments</title>
		<author>
			<persName><forename type="first">Gjd</forename><surname>Hengstman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bgm</forename><surname>Van Engelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wtmv</forename><surname>Egberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Van Venrooij</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="476" to="482" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Love</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Leff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Frazer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medicine</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="360" to="374" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Clinical and serological characteristics of 125 Dutch myositis patients</title>
		<author>
			<persName><forename type="first">Gjd</forename><surname>Hengstman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Brouwer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Vree</forename><surname>Egberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wtm</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol</title>
		<imprint>
			<biblScope unit="volume">249</biblScope>
			<biblScope unit="page" from="69" to="75" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Kissel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Halterman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Rammohan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Mendell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="26" to="30" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Microvascular deposition of complement membrane attack complex in dermatomyositis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Kissel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Mendell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Rammohan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">314</biblScope>
			<biblScope unit="page" from="329" to="334" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments</title>
		<author>
			<persName><forename type="first">M</forename><surname>Basta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="1729" to="1735" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Analysis of cytokine expression in muscle in inflammatory myopathies, Duchennes dystrophy and non-weak controls</title>
		<author>
			<persName><forename type="first">I</forename><surname>Lundberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Brengman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuroimmunol</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="9" to="16" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Intercellular adhesion molecule-I expression is upregulated in patients with dermatomyositis (DM)</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page">268</biblScope>
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Cytokine expression profiles in idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Tews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Goebel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="342" to="347" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Differential expression of chemokines in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">De</forename><surname>Bleecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Paepe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Vanwalleghem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">E</forename><surname>Schroder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="1779" to="1785" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Monoclonal antibody analysis of mononuclear cells in myopathies: III, immunoelectron microscopy aspects of cellmediated muscle fiber injury</title>
		<author>
			<persName><forename type="first">K</forename><surname>Arahata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="112" to="125" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Tezak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Hoffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Lutz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="page" from="4154" to="4163" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="498" to="507" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<monogr>
		<title level="m" type="main">For personal use. Only reproduce with permission from The Lancet</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Immunocytochemical study of CD45 T cell isoforms in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">De</forename><surname>Bleecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">146</biblScope>
			<biblScope unit="page">1178</biblScope>
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Differential expression of perforin in muscle-infiltrating T cell in polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">N</forename><surname>Goebels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Michaelis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Engelhardt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page">2905</biblScope>
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Cytotoxic T lymphocytes: all roads lead to death</title>
		<author>
			<persName><forename type="first">M</forename><surname>Barry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Bleackley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Immunol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="401" to="409" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Cytotoxic mechanisms in inflammatory myopathies: co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells</title>
		<author>
			<persName><forename type="first">L</forename><surname>Behrens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page">929</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">MHC class I mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="1205" to="1209" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">T cell apoptosis in inflammatory neuromuscular disorders associated with human immunodeficiency virus infection</title>
		<author>
			<persName><forename type="first">C</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Toyka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Said</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Hartung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="79" to="83" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">The inhibition of apoptosis in myositis and in normal muscle cells</title>
		<author>
			<persName><forename type="first">K</forename><surname>Nagaraju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Casciola-Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rosen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="page" from="5459" to="5465" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Expression of human IAP-like protein in skeletal muscle: an explanation for the rare incidence of muscle fiber apoptosis in T-cell mediated inflammatory myopathies</title>
		<author>
			<persName><forename type="first">M</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuroimmunol</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="1" to="5" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Analysis of T cell receptor repertoire of muscle infiltrating T lymphocytes in polymyositis: restricted V a/b rearrangements may indicated antigendriven selection</title>
		<author>
			<persName><forename type="first">R</forename><surname>Mantegazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Andreetta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bernasconi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="2880" to="2886" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8 T cells</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ernst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Iglesias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dornmair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wekerle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">181</biblScope>
			<biblScope unit="page" from="1863" to="1868" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Predominant T cell receptor variable and joining gene expression by muscleinfiltrating lymphocytes in the idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>O'hanlon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="2569" to="2576" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Clonal biases of peripheral CD8 T cell repertoire directly reflect local inflammation in polymyositis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Nishio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Miyasaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kohsaka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">167</biblScope>
			<biblScope unit="page" from="4051" to="4058" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomysitis patients</title>
		<author>
			<persName><forename type="first">O</forename><surname>Benveniste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cherin</forename><forename type="middle">P</forename><surname>Maisonobe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">167</biblScope>
			<biblScope unit="page" from="3521" to="3529" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">The molecular and cellular pathology of inflammatory muscle diseases</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="300" to="306" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Polymyositis mediated by T lymphocytes that express the ␥/␦ receptor</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Harper</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">324</biblScope>
			<biblScope unit="page" from="877" to="881" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Autoaggressive myocytotoxic T lymphocytes expressing an unusual ␥␦ T cell receptor</title>
		<author>
			<persName><forename type="first">G</forename><surname>Pluschke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ruegg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">176</biblScope>
			<biblScope unit="page" from="1785" to="1789" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">An autoreactive ␥␦ TCR derived from a polymyositis lesion</title>
		<author>
			<persName><forename type="first">H</forename><surname>Wiendl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Malotka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Holzwarth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="page" from="515" to="521" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Skeletal muscle fibers express major histocompativility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">P</forename><surname>Englund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lindroos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nennesmo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Klareskog</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">E</forename><surname>Lundberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="page" from="1263" to="1273" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Modulation of MHC class II antigen expression in human myoblasts after treatment with IFN-gamma</title>
		<author>
			<persName><forename type="first">R</forename><surname>Mantegazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mitchell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Travis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Blau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Steinman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="1128" to="1132" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Constitutive and cytokineinduced expression of human leukocyte antigens and cell adhesion molecules by human myotubes</title>
		<author>
			<persName><forename type="first">D</forename><surname>Michaelis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Goebels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="1142" to="1149" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Induction of HLA-DR expression on human myoblasts with interferon-gamma</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="503" to="508" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies</title>
		<author>
			<persName><forename type="first">K</forename><surname>Nagaraju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Raben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Loeffler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="9209" to="9214" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Increased expression of interleukin 1␣ and MHC Class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Nyberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Wikman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nennesmo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Lundberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="940" to="948" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA-G</title>
		<author>
			<persName><forename type="first">H</forename><surname>Wiendl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Behrens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Maier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="679" to="684" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">The nonclassical MHC molecule HLA-G protects human muscle cells from immunemediated lysis: implications for myoblast transplantation and gene therapy</title>
		<author>
			<persName><forename type="first">H</forename><surname>Mitsdoerffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hofmeister</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="176" to="185" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR and CDR3 spectratype analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Wiesener</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Babbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="4090" to="4095" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">The right place at the right time: novel B7 family members regulate effector T cell function</title>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Sha</forename><forename type="middle">Wc</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Immunol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="384" to="390" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Dynamics of the immunological synapse: finding, establishing and solidifying a connection</title>
		<author>
			<persName><forename type="first">Davis</forename><forename type="middle">Mm</forename><surname>Mf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Immunol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="66" to="74" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions</title>
		<author>
			<persName><forename type="first">L</forename><surname>Kerschensteiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Misgeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Goebels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Wekerle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hohlfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">161</biblScope>
			<biblScope unit="page" from="5943" to="5951" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNA in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">K</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Dalakas</forename><surname>Mc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">155</biblScope>
			<biblScope unit="page" from="453" to="460" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15 and monocyte chemoattractant protein-1 production</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kawaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Harigai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="page" from="6593" to="6600" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Muscle fibers and cultured muscle cells express the B7.1/2 related costimulatory molecule ICOSL: implications for the pathogenesis of inflammatory myopathies</title>
		<author>
			<persName><forename type="first">H</forename><surname>Mitsdoerffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="1026" to="1035" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Signal transducer and activator of transcription 1 in human muscle: implications in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">I</forename><surname>Gallardo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gimeno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Serrano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ferrer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Juarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">151</biblScope>
			<biblScope unit="page" from="81" to="88" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">Molecular immunology and genetics of inflammatory muscle diseases</title>
		<author>
			<persName><surname>Mc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="1509" to="1512" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Bleecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">I</forename><surname>Meire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Declercq</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Van Aken</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuromusc Disord</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">239</biblScope>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">Tumor necrosis factor-␣ expression in muscles of polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Inukai</forename><forename type="middle">A</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Doyu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Takano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sobue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="585" to="588" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">Necrotizing myopathy induced by overexpression of interferon-␥ in transgenic mice</title>
		<author>
			<persName><surname>Gd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Calcutt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Garrett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="156" to="165" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">Synergistic cytotoxic effect of interferon ␥ and tumor necrosis factor ␣ on cultured human muscle cells</title>
		<author>
			<persName><forename type="first">Plotkin</forename><forename type="middle">Z</forename><surname>Ae</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1698" to="1703" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">Interleukin-1 (IL-1) is toxic to human muscle</title>
		<author>
			<persName><forename type="first">M</forename><surname>Monzon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page">132</biblScope>
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">Transforming growth factor-␤2 is elevated in skeletal muscle disorders</title>
		<author>
			<persName><forename type="first">N</forename><surname>Mclennan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">S</forename><surname>Nonaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Koishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Baker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Tooke-</forename><surname>Hammond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="889" to="898" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main">A controlled trial of highdose intravenous immunoglobulin infusions as treatment for dermatomyositis</title>
		<author>
			<persName><forename type="first">Illa</forename><forename type="middle">I</forename><surname>Mc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Dambrosia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">329</biblScope>
			<biblScope unit="page" from="1993" to="2000" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">Downregulation of TGF-␤1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin</title>
		<author>
			<persName><forename type="first">K</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Semino-</forename><surname>Mora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Granger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="99" to="104" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">Chemokines and the tissue-specific migration of lymphocytes</title>
		<author>
			<persName><surname>Ej</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Butcher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="1" to="4" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation</title>
		<author>
			<persName><forename type="first">M</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bernasconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Baggi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>De Waal Maleft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mantegazza</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int Immunol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1329" to="1335" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main">Expression of interferon-gamma inducible chemokines in the muscles of patients with inclusion body myositis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Vasconcelos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">M</forename><surname>Semino-Mora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Granger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page">A390</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies</title>
		<author>
			<persName><forename type="first">P</forename><surname>Bernasconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Megna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Galbiati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cornelio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mantegazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="164" to="169" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies</title>
		<author>
			<persName><forename type="first">Dalakas</forename><surname>Yc</surname></persName>
		</author>
		<author>
			<persName><surname>Mc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="65" to="71" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">Expression of specific matrix metalloproteinases in inflammatory myopathies</title>
		<author>
			<persName><surname>Bc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Clements</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="341" to="351" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b123">
	<monogr>
		<title level="m" type="main">Viral related muscle disease</title>
		<editor>Engel AG, ed. Myology</editor>
		<imprint>
			<publisher>McGraw Hill (in press</publisher>
			<pubPlace>New York</pubPlace>
		</imprint>
		<respStmt>
			<orgName>MC</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main">Viruses in the idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Love</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
		<ptr target="www.thelancet.com125LeffRL" />
	</analytic>
	<monogr>
		<title level="j">THE LANCET</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope unit="page" from="1192" to="1195" />
			<date type="published" when="1992">September 20. 2003. 1992</date>
		</imprint>
	</monogr>
	<note>Lancet</note>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main">Absence of persistent infection with enteroviruses in muscles of patients with inflammatory myopathies</title>
		<author>
			<persName><forename type="first">M</forename><surname>Monzon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="219" to="222" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main">Polymyositis in an immunodeficiency disease in monkeys induced by a type D retrovirus</title>
		<author>
			<persName><forename type="first">London</forename><forename type="middle">Wt</forename><surname>Mc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gravell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Sever</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="569" to="572" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main">Polymyositis in patients with AIDS</title>
		<author>
			<persName><surname>Mc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Pezeshkpour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gravell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Sever</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">256</biblScope>
			<biblScope unit="page" from="2381" to="2383" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main">HTLV-1 and polymyositis in Jamaica</title>
		<author>
			<persName><surname>Ostc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rodgers-Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Char</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1184" to="1187" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b129">
	<analytic>
		<title level="a" type="main">Neuromuscular diseases associated with human immunodeficiency virus infection</title>
		<author>
			<persName><forename type="first">Pezeshkpour</forename><surname>Mc</surname></persName>
		</author>
		<author>
			<persName><surname>Gh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="38" to="48" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b130">
	<analytic>
		<title level="a" type="main">Polymyositis in patients infected with HTLV-I: The role of the virus in the cause of the disease</title>
		<author>
			<persName><forename type="first">M</forename><surname>Monzon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Illa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="643" to="649" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main">Inclusion body myositis in HIV-I and HTLV-I infected patients</title>
		<author>
			<persName><forename type="first">Leon</forename><forename type="middle">-</forename><surname>Ej</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Monzon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Semino-Mora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="1887" to="1893" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b132">
	<analytic>
		<title level="a" type="main">Immunocytochemical and virological characteristics of HIV-associated inflammatory myopathies: similarities with seronegative polymyositis</title>
		<author>
			<persName><forename type="first">I</forename><surname>Nath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="474" to="481" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b133">
	<analytic>
		<title level="a" type="main">Mechanisms for the induction of autoimmunity by infectious agents</title>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="1097" to="1104" />
			<date type="published" when="2001">2001</date>
			<publisher>KW</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b134">
	<analytic>
		<title level="a" type="main">How to diagnose and treat the inflammatory myopathies</title>
		<author>
			<persName><surname>Mc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Neurol</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="365" to="369" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b135">
	<analytic>
		<title level="a" type="main">Idiopathic inflammatory myopathy: management and prognosis</title>
	</analytic>
	<monogr>
		<title level="j">Rheum Dis Clin N Am</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="979" to="1001" />
			<date type="published" when="2002">2002</date>
		</imprint>
		<respStmt>
			<orgName>CV</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b136">
	<analytic>
		<title level="a" type="main">Azathioprine and prednisone for polymyositis: a controlled clinical trial</title>
		<author>
			<persName><forename type="first">Worthington</forename><forename type="middle">Jw</forename><surname>Tw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Combs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Ilstrup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="365" to="369" />
			<date type="published" when="1980">1980</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b137">
	<analytic>
		<title level="a" type="main">Cyclosporin in juvenile dermatomyositis</title>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Hasson</forename><forename type="middle">N</forename><surname>Saunders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="1063" to="1066" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b138">
	<analytic>
		<title level="a" type="main">Cyclosporine A as first choice for dermatomyositis</title>
		<author>
			<persName><surname>Jm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Herrero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Casademont</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="381" to="382" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b139">
	<analytic>
		<title level="a" type="main">Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases</title>
		<author>
			<persName><forename type="first">V</forename><surname>Cornblath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Griffin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>'brien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Drachman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="94" to="96" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b140">
	<analytic>
		<title level="a" type="main">The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy</title>
		<author>
			<persName><surname>Me</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Hicks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="1225" to="1228" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b141">
	<analytic>
		<title level="a" type="main">Cyclophosphamide in severe polymyositis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Grv</forename><surname>Neri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Bravo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Bono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="1138" to="1139" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b142">
	<analytic>
		<title level="a" type="main">Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Reuter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="1215" to="1220" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b143">
	<analytic>
		<title level="a" type="main">A randomized doubleblind controlled trial of plasma exchange and leukapheresis in patients with polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">Leitman</forename><surname>Fw</surname></persName>
		</author>
		<author>
			<persName><surname>Sf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Cronin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">326</biblScope>
			<biblScope unit="page" from="1380" to="1384" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b144">
	<analytic>
		<title level="a" type="main">Total body irradiation in the treatment of intractable polymyositis and dermatomyositis</title>
		<author>
			<persName><surname>Mc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Polymyositis and dermatomyositis</title>
				<editor>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</editor>
		<meeting><address><addrLine>Stoneham; Butterworth</addrLine></address></meeting>
		<imprint>
			<date type="published" when="1988">1988</date>
			<biblScope unit="page" from="281" to="291" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b145">
	<analytic>
		<title level="a" type="main">Efficacy of intravenous immunoglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients</title>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Herson</forename><forename type="middle">S</forename><surname>Wechsler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="162" to="168" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b146">
	<analytic>
		<title level="a" type="main">Intravenous immunoglobulin therapy for neurological diseases</title>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="721" to="730" />
			<date type="published" when="1997">1997</date>
		</imprint>
		<respStmt>
			<orgName>MC</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b147">
	<analytic>
		<title level="a" type="main">Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis and polymyositis</title>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="537" to="545" />
			<date type="published" when="1998">1998</date>
		</imprint>
		<respStmt>
			<orgName>MC</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b148">
	<analytic>
		<title level="a" type="main">Immunotherapies in the treatment of neuromuscular diseases</title>
		<author>
			<persName><surname>Mc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Neuromuscular disorders in clinical practice</title>
				<editor>
			<persName><forename type="first">B</forename><surname>Katirji</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Kaminski</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Preston</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Ruff</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Shapiro</surname></persName>
		</editor>
		<meeting><address><addrLine>Woburn, MA</addrLine></address></meeting>
		<imprint>
			<publisher>Butterworth-Heineman</publisher>
			<date type="published" when="2002">2002</date>
			<biblScope unit="page" from="364" to="383" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b149">
	<analytic>
		<title level="a" type="main">Treatment of dermatomyositis and polymyositis</title>
		<author>
			<persName><forename type="first">Isenberg</forename><surname>Ehs</surname></persName>
		</author>
		<author>
			<persName><surname>Da</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="7" to="13" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b150">
	<analytic>
		<title level="a" type="main">Progress in inflammatory myopathies: good but not good enough</title>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="569" to="573" />
			<date type="published" when="2001">2001</date>
		</imprint>
		<respStmt>
			<orgName>MC</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b151">
	<analytic>
		<title level="a" type="main">The basis of immunotherapy in neurological disease</title>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Diseases of the nervous system: clinical neuroscience and therapeutic principles</title>
				<editor>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Asbury</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">G</forename><surname>Mckhann</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">W</forename><forename type="middle">I</forename><surname>Mcdonald</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Goadsby</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Mcarthur</surname></persName>
		</editor>
		<meeting><address><addrLine>Cambridge</addrLine></address></meeting>
		<imprint>
			<publisher>Cambridge University Press</publisher>
			<date type="published" when="2002">2002</date>
			<biblScope unit="page" from="1527" to="1546" />
		</imprint>
	</monogr>
	<note>3rd edn</note>
</biblStruct>

<biblStruct xml:id="b152">
	<analytic>
		<title level="a" type="main">Immunotherapy in autoimmune neuromuscular disorders</title>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Dalakas</forename><surname>Mc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Toyka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Neurology</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="22" to="32" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b153">
	<analytic>
		<title level="a" type="main">Long-term prognosis of 69 patients with dermatomyositis or polymyositis</title>
		<author>
			<persName><surname>Ym</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Berthelot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Abbas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Mussini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Prost</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Rheumatol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="263" to="274" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b154">
	<analytic>
		<title level="a" type="main">Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality</title>
		<author>
			<persName><surname>Sm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ioannou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Moss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Isenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="22" to="26" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b155">
	<analytic>
		<title level="a" type="main">Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis</title>
		<author>
			<persName><forename type="first">I</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Hachulla</forename><forename type="middle">E</forename><surname>Hatron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">Y</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="2230" to="2237" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
